Publicaciones en colaboración con investigadores/as de Hospital Universitario de Canarias (10)

2022

  1. Early clinical outcomes after transaxillary versus transfemoral TAVI. Data from the Spanish TAVI registry

    Revista Espanola de Cardiologia, Vol. 75, Núm. 6, pp. 479-487

2019

  1. High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients

    BMC neurology, Vol. 19, Núm. 1, pp. 167

  2. Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients

    Journal of Critical Care, Vol. 51, pp. 117-121

2015

  1. Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction

    BMC Neurology, Vol. 15, Núm. 1

2014

  1. Association between serum tissue inhibitor of matrix metalloproteinase-1 levels and mortality in patients with severe brain trauma injury

    PLoS ONE, Vol. 9, Núm. 4

  2. Association of sepsis-related mortality with early increase of TIMP-1/MMP-9 ratio

    PLoS ONE, Vol. 9, Núm. 4

2013

  1. The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis

    Critical Care, Vol. 17, Núm. 3

2012

  1. Synergistic effect of thrombin and CD40 ligand on endothelial matrix metalloproteinase-10 expression and microparticle generation in vitro and in vivo

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 32, Núm. 6, pp. 1477-1487

2011

  1. Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis

    Critical Care, Vol. 15, Núm. 2

2009

  1. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis

    Critical Care, Vol. 13, Núm. 5